<DOC>
	<DOCNO>NCT00989586</DOCNO>
	<brief_summary>A phase I dose escalation study veltuzumab milatuzumab relapse refractory B-cell NHL . The phase I study follow pilot phase II study .</brief_summary>
	<brief_title>Veltuzumab Milatuzumab Treating Patients With Relapsed Refractory B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>A phase I/II study veltuzumab combine milatuzumab relapse refractory non-Hodgkin 's lymphoma . Both agent well-tolerated early phase clinical test infusion reaction primary observed toxicity . Preclinical test vitro vivo demonstrate single agent activity veltuzumab milatuzumab . In mantle cell lymphoma cell line SCID mouse model , synergist effect observe milatuzumab combine rituximab . Veltuzumab several advantage rituximab include slow off-rates , short infusion time , high potency , improve therapeutic response animal model . Previous ongoing clinical investigation support concept combine monoclonal antibody NHL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm Bcell nonHodgkin lymphoma ( NHL ) , include follow : Marginal zone lymphoma Waldenstrom macroglobulinemia ( lymphoplasmacytic lymphoma ) Follicular lymphoma Mantle cell lymphoma Relapsed refractory disease ≥ 1 prior therapy Patients rituximabrefractory disease ( define less partial response prior rituximabcontaining regimen ) rituximabsensitive disease ( define complete response partial response last rituximabcontaining regimen [ provide ≥ 3 month since last dose rituximab ] ) eligible . Age &gt; 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patients must normal organ marrow function define : Absolute neutrophil count ≥ 1000/μL Platelets ≥ 75,000/μL Total bilirubin ≤ 2.0 X institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional upper limit normal Creatinine ≤ 2.0 mg/dL Patients relapse stem cell transplant eligible trial . Patients active Hepatitis B infection eligible . Nonpregnant nonnursing . Women child bear potential men must agree use contraception prior study entry duration study participation . Must possess ability understand willingness sign write informed consent document . Phase II Must measurable disease , define least one lesion accurately measure least one dimension &gt; 10 mm case Waldenstrom 's macroglobulinemia , presence IgM paraprotein level 2x upper limit normal . Must recover toxicity prior therapy radiation ( exclude alopecia ) . No known CNS lymphoma . History document human antiglobulin antibody . No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation . HIVpositive patient . Pregnant woman . Patients secondary malignancy exception nonmelanomatous skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>MALT lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
</DOC>